SCHEMBL3857024

SCHEMBL3857024

Cc1ccc(Cn2c(C)c(C[C@H](N)C(=O)OCl)c3ccccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.51
HDAC6 Q9UBN7 4/20 0.51
PLA2G2A P14555 2/20 0.51
P2RX4 Q99571 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.48
GFER P55789 1/20 0.48
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NOD2 Q9HC29 1/20 0.46
NOD1 Q9Y239 1/20 0.46
RECQL P46063 1/20 0.46
MAPK10 P53779 1/20 0.46
THRA P10827 4/20 0.45
THRB P10828 4/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848774 0.92 HDAC1 (0.50) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3855367 0.91 HDAC1 (0.49) HDAC1HDAC6PLA2G2AP2RX4PTGDR2
SCHEMBL3848975 0.91 LMNA (0.55) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3853781 0.88 HDAC1 (0.49) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3848949 0.88 HDAC1 (0.47) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3855485 0.87 PLA2G2A (0.50) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3848329 0.85 KDM4E (0.50) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3854421 0.80 HDAC1 (0.48) HDAC1HDAC6PLA2G2APTGDR2GFER
SCHEMBL3854166 0.80 PLA2G2A (0.47) HDAC1HDAC6PLA2G2AGFERKDM4E
SCHEMBL3858093 0.79 PLA2G2A (0.48) HDAC1HDAC6PLA2G2APTGDR2GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 HDAC1 589/4885HDAC6 571/4885PLA2G2A 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.